改变了产科实践的临床试验:慢性高血压和怀孕 (CHAP) 试验
Clinical obstetrics and gynecology
|March 11, 2024
概括
在怀孕期间治疗轻度慢性高血压可以降低产前,早产和胎儿死亡的风险. 该CHAP试验导致更新的指导方针,建议在怀孕期间治疗慢性高血压,血压目标低于140/90mmHg.
科学领域:
- 产科和妇科 产科和妇科
- 心脏病学 心脏病学
- 周围生理学 周围生理学
背景情况:
- 孕期慢性高血压 (CHTN) 对母亲和胎儿都有风险.
- 怀孕期间轻度CHTN的以前治疗指南不那么明确.
研究的目的:
- 描述CHTN在怀孕期间治疗建议的演变.
- 分析CHTN和怀孕 (CHAP) 试验对产科实践的影响.
主要方法:
- 这项研究侧重于美国多中心CHAP试验的发现和影响.
- 对轻度CHTN的抗高血压治疗与不治疗的比较.
主要成果:
- 在怀孕期间对轻度CHTN (血压<160/105 mmHg) 进行抗高血压治疗以达到<140/90 mmHg的目标,可降低复合风险.
- 减少的关键结局包括重叠的严重子前,预示早产 (<35周),胎盘断裂和胎儿/新生儿死亡.
- 在治疗组中使用的主要药物是Labetalol和nifedipine.
结论:
- 该CHAP试验表明,在怀孕期间治疗轻度CHTN有显著的益处.
- 美国最新的专业社会建议现在主张在怀孕期间治疗CHTN,以达到<140/90 mmHg的血压目标.
更多相关视频
相关概念视频
Clinical Trials
6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.7K
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Adrenergic Antagonists: ɑ and β-Receptor Blockers
447
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
447
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
126
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
126
Teratogenicity
2.4K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.4K
Hormonal Regulation
33.1K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.1K


